China Medical City To Acquire Korean Biotechnology
This article was originally published in PharmAsia News
Executive Summary
Six Korean R&D institutions and eight companies in biopharmaceuticals recently signed MOUs for 16 programs with China Medical City in Jiangsu province. The Daejeon City representatives from Korea will be introducing world-class new drug R&D technologies into China, as well as the industrialization and production of health care and pharmaceutical products. Since its establishment, China Medical City has been targeting Korean investors. Last year, it signed an agreement with its counterpart to set up a center that offers collaborative biopharmaceutical services to Korean enterprises operating in the medical city. (Click here for more - Chinese Language)